Millendo Starts New Trial On Polycystic Ovary Syndrome Drug
ANN ARBOR — The pharma startup Millendo Therapeutics Inc. announced the start of a Phase 2b clinical trial to assess the efficacy of drug candidate MLE4901, a non-hormonal therapy for …
Ann Arbor Pharma Reports Good News From Clinical Trial
ANN ARBOR — A new drug to treat polycystic ovary syndrome got good results in a Phase 2a clinical trial, according to the drug’s developer, Millendo Therapeutics Inc. of Ann …
Ann Arbor Pharma Firm Gets $62M To Commercialize Drug For Ovarian Disease
ANN ARBOR — Millendo Therapeutics Inc., the Ann Arbor pharma firm, announced an exclusive license agreement with the pharmaceutical giant AstraZeneca for the worldwide development and commercialization rights to AZD4901, …